Scholarlink

Introduction <p>Psoriasis involving special or high-impact areas (scalp, nails, palms/soles, genitalia) is associated with a disproportionate functional and psychological burden that is often underestimated by conventional severity scores and remains challenging to treat effectively. This study compared the real-world efficacy and safety of three interleukin (IL)-23p19 inhibitors—risankizumab, guselkumab, and tildrakizumab 200&#xa0;mg—in patients with moderate-to-severe plaque psoriasis with involvement of high-impact sites.</p> Methods <p>This multicenter retrospective study included 670 patients treated for at least 52&#xa0;weeks across 37 Italian dermatology centers. Patients received risankizumab (<i>n</i> = 254), guselkumab (<i>n</i> = 177), or tildrakizumab 200&#xa0;mg (<i>n</i> = 239) according to approved regimens. Effectiveness was assessed using Psoriasis Area Severity Index (PASI) and site-specific Physician’s Global Assessment (PGA) scores (scalp, nails, palms/soles, genitalia) at weeks&#xa0;4, 16, 36, and 52. Safety was evaluated through reported adverse events.</p> Results <p>Risankizumab demonstrated the fastest and most pronounced reduction in PASI, achieving PASI90 and PASI100 responses in 89.6% and 82.1% of patients at week&#xa0;52, respectively. Tildrakizumab 200&#xa0;mg showed a slower onset but comparable long-term efficacy, particularly in nail and palmoplantar psoriasis. At week&#xa0;52, complete nail clearance (fn-PGA = 0) was achieved in 90.0% of patients treated with risankizumab, 76.7% with tildrakizumab, and 66.7% with guselkumab. Palmoplantar and genital psoriasis showed near-complete resolution across all treatment groups by week&#xa0;52. Scalp involvement improved markedly with all agents, with lower residual disease observed with risankizumab. All treatments were well tolerated, with infrequent and predominantly mild adverse events and no major safety concerns.</p> Conclusion <p>In real-world clinical practice, IL-23p19 inhibitors provide high and sustained efficacy in psoriasis affecting high-impact sites. Risankizumab offers faster and deeper responses, while tildrakizumab 200&#xa0;mg represents an effective long-term option, particularly in patients with higher BMI or more treatment-resistant disease. These findings support a personalized approach to biologic selection based on disease localization, patient characteristics, and therapeutic goals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月16日

查看全文
  • Emanuele Trovato,
  • Alessandra Cartocci,
  • Francesca Gaiani,
  • Francesco Messina,
  • Luca Mastorino,
  • Nicole Macagno,
  • Andrea Carugno,
  • Marco Campoli,
  • Maria Concetta Fargnoli,
  • Viviana Lora,
  • Agnese Rossi,
  • Helena Gioacchini,
  • Luca Potestio,
  • Giovanni Marco D’Agostino,
  • Martina Maurelli,
  • Giampiero Girolomoni,
  • Marco Romanelli,
  • Valentina Dini,
  • Francesco Loconsole,
  • Francesca Satolli,
  • Gianluca Pagnanelli,
  • Claudia Lasagni,
  • Andrea Michelerio,
  • Martina Dragotto,
  • Piergiorgio Malagoli,
  • Nicola Zerbinati,
  • Diego Orsini,
  • Anna Campanati,
  • Matteo Megna,
  • Tommaso Bianchelli,
  • Marco Manfredini,
  • Davide Strippoli,
  • Clara De Simone,
  • Franco Rongioletti,
  • Santo Mercuri,
  • Massimiliano Nicolini,
  • Giancarlo Lazzaro Danzuso,
  • Andrea Altomare,
  • Carlo Carrera,
  • Aldo Cuccia,
  • Claudio Guarneri,
  • Claudia Giofre’,
  • Alessandro Borghi,
  • Anna Scuderi,
  • Nicoletta Bernardini,
  • Federico Bardazzi,
  • Francesco Cona,
  • Alexandra Brunasso Vannetti,
  • Annunziata Raimondo,
  • Vito Di Lernia,
  • Carmen Fiorella,
  • Pietro Morrone,
  • Alessandra Capo,
  • Giulia Rech,
  • Antonio Costanzo,
  • Simone Ribero,
  • Alessandra Narcisi

摘要

Introduction

Psoriasis involving special or high-impact areas (scalp, nails, palms/soles, genitalia) is associated with a disproportionate functional and psychological burden that is often underestimated by conventional severity scores and remains challenging to treat effectively. This study compared the real-world efficacy and safety of three interleukin (IL)-23p19 inhibitors—risankizumab, guselkumab, and tildrakizumab 200 mg—in patients with moderate-to-severe plaque psoriasis with involvement of high-impact sites.

Methods

This multicenter retrospective study included 670 patients treated for at least 52 weeks across 37 Italian dermatology centers. Patients received risankizumab (n = 254), guselkumab (n = 177), or tildrakizumab 200 mg (n = 239) according to approved regimens. Effectiveness was assessed using Psoriasis Area Severity Index (PASI) and site-specific Physician’s Global Assessment (PGA) scores (scalp, nails, palms/soles, genitalia) at weeks 4, 16, 36, and 52. Safety was evaluated through reported adverse events.

Results

Risankizumab demonstrated the fastest and most pronounced reduction in PASI, achieving PASI90 and PASI100 responses in 89.6% and 82.1% of patients at week 52, respectively. Tildrakizumab 200 mg showed a slower onset but comparable long-term efficacy, particularly in nail and palmoplantar psoriasis. At week 52, complete nail clearance (fn-PGA = 0) was achieved in 90.0% of patients treated with risankizumab, 76.7% with tildrakizumab, and 66.7% with guselkumab. Palmoplantar and genital psoriasis showed near-complete resolution across all treatment groups by week 52. Scalp involvement improved markedly with all agents, with lower residual disease observed with risankizumab. All treatments were well tolerated, with infrequent and predominantly mild adverse events and no major safety concerns.

Conclusion

In real-world clinical practice, IL-23p19 inhibitors provide high and sustained efficacy in psoriasis affecting high-impact sites. Risankizumab offers faster and deeper responses, while tildrakizumab 200 mg represents an effective long-term option, particularly in patients with higher BMI or more treatment-resistant disease. These findings support a personalized approach to biologic selection based on disease localization, patient characteristics, and therapeutic goals.